Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.15 USD
Change Today +0.0075 / 5.17%
Volume 62.1K
INNV On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

innovus pharmaceuticals inc (INNV) Snapshot

Open
$0.15
Previous Close
$0.14
Day High
$0.15
Day Low
$0.14
52 Week High
09/22/14 - $0.50
52 Week Low
07/8/14 - $0.11
Market Cap
6.2M
Average Volume 10 Days
50.4K
EPS TTM
$-0.19
Shares Outstanding
40.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNOVUS PHARMACEUTICALS INC (INNV)

Related News

No related news articles were found.

innovus pharmaceuticals inc (INNV) Related Businessweek News

No Related Businessweek News Found

innovus pharmaceuticals inc (INNV) Details

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription pharmaceutical and consumer health products in the United States and internationally. The company’s products include Zestra, a non-medicated, patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity low osmolality water-based lubricant; and Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health. It has an agreement with Laboratorios Q Pharma to distribute and commercialize Androferti, a natural supplement that supports male reproductive health and sperm quality; and develops Fluticare, a nasal spray in the form of fluticasone propionate, which is in FDA approval stage. The company markets its products directly or through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.

3 Employees
Last Reported Date: 03/31/15

innovus pharmaceuticals inc (INNV) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

innovus pharmaceuticals inc (INNV) Key Developments

Innovus Pharmaceuticals, Inc. Enters into an Exclusive Marketing and Distribution Agreement with Oz Biogenics

Innovus Pharmaceuticals, Inc. announced it has entered into an exclusive marketing and distribution agreement with Oz Biogenics based in Australia under which Innovus Pharma has granted to Oz Biogenics an exclusive ten-year license and distribution rights to market and sell Innovus Pharma's products including Zestra to increase Female Sexual Arousal and Desire and Satisfaction, EjectDelay for treating premature ejaculation, Sensum+ to increase penile sensitivity, Vesele for sexual functions and cognitive responses and Zestra Glide the high viscosity water based lubricant. Oz Biogenics is in the process of negotiating commercial agreements with pharmaceutical companies in those countries to promote the product in the medical and mainstream channels. The annual minimum orders are approximately $865,000 over the ten year term of the agreement.

Innovus Pharmaceuticals, Inc. Enters Into Exclusive License and Distribution Agreement with BroadMed SAL

On April 8, 2015, Innovus Pharmaceuticals, Inc. announced that it had entered into an exclusive license and distribution agreement with BroadMed SAL under which Innovus Pharma granted to BroadMed an exclusive license to market and sell in Lebanaon Innovus' product Sensum+ to increase penile sensitivity. Under the agreement, Innovus Pharma is eligible to receive up to $11.1 million in upfront and sales milestone payments plus double-digit tiered royalties based on BroadMed's net sales.

Innovus Pharmaceuticals, Inc. Reports Revenue Results for the Year 2014

Innovus Pharmaceuticals, Inc. reported revenue results for the year 2014. For the year, the company reported revenues increased to over $1,000,000 in 2014 up from $6,641 in 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNV:US $0.15 USD +0.0075

INNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INNV.
View Industry Companies
 

Industry Analysis

INNV

Industry Average

Valuation INNV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOVUS PHARMACEUTICALS INC, please visit www.innovuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.